Indian Journal of Urology Users online:1616  
Home Current Issue Ahead of print Editorial Board Archives Symposia Guidelines Subscriptions Login 
Print this page  Email this page Small font sizeDefault font sizeIncrease font size
Year : 2001  |  Volume : 17  |  Issue : 2  |  Page : 124-126

B. C. G. plus recombinant interferon α2b in superficial bladder cancer

Departments of Urology and Immunology, Institute of Medical Sciences, B.H. U., Varanasi, India

Correspondence Address:
P B Singh
Dept. of Urology, Institute of Medical Sciences, B.H.U., Varanasi - 221 005
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

We have studied the efficacy of adjuvant therapy in the form of low dose B.C.G. and interferon alpha 2b. In the present study 7patients with superficial bladder car­cinoma (6 recurrent and I primary) have been treated by TURBT and intravesical instillation of B. C. G. 80 mg plus interferon alpha 2b 10 million units weekly for 8 weeks. All patients accepted the therapy without sig­nificant morbidity and complication. Follow-up,period ranges between 11-16 months and none of the patients have developed recurrence till date. Interferon alpha 2b along with B.C.G. is a good al­ternative agent, for prophylaxis in case of high grade and recurrent bladder tumour

[FULL TEXT] [PDF Not available]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded0    
    Comments [Add]    

Recommend this journal